Evidence map›Paper›PMID 32705485›Full record

ReviewInfectious diseases and therapy2020

A Comprehensive Review of Meningococcal Disease Burden in India.

Ashok Kumar Dutta, Subramanian Swaminathan, Veronique Abitbol, Shafi Kolhapure, Sripriya Sathyanarayanan

Open access · goldAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Structural characterization of a nonhydrolyzing UDP-GlcNAc 2-epimerase from Neisseria meningitidis serogroup A.Acta crystallographica. Section F, Structural biology communications · 2020
    Article
  16. Need to Study the Health Impact and Economics of Adult Vaccination with India in Focus.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ashok Kumar DuttaDepartment of Pediatrics, Indraprastha Apollo Hospitals, New Delhi, India.
Subramanian SwaminathanDepartment of Infectious Diseases, Gleneagles Global Hospitals, Chennai/Bangalore, India.
Veronique AbitbolGlobal Medical Affairs, GSK, Rueil-Malmaison, France.ORCID http://orcid.org/0000-0003-0369-7715
Shafi KolhapureMedical Affairs Department, GSK, Mumbai, India.ORCID http://orcid.org/0000-0002-3183-1259
Sripriya SathyanarayananMedical Affairs Department, GSK, Mumbai, India. sripriya.x.sathyanarayanan@gsk.com.
GlaxoSmithKline (India) · INGlaxoSmithKline (France) · FRGlobal Hospitals · INIndraprastha Apollo Hospitals · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMeningococcal disease caused by Neisseria meningitidis has a high case fatality rate. Of 12 distinct serogroups, A, B, C, W-135 (W) and Y cause the majority of infections. The meningococcal disease burden and epidemiology in India are not reliably known. Hence, we performed a narrative review with a systematically conducted search to summarize information on meningococcal disease burden and epidemiology and vaccination recommendations for meningococcal disease in India.

methodsA search of Medline and Embase databases was undertaken to identify relevant publications published in the last 25 years.

resultsResults from 32 original publications, 11 of which were case reports, suggest a significant burden of meningococcal disease and related complications. Meningococcal disease is increasingly reported among adolescents and adults, and large outbreaks have been reported in this population. Meningococcal disease in India is caused almost exclusively by serogroup A; serogroups B, C, W and Y have also been documented. Meningococcal disease burden data remain unreliable because of limited disease surveillance, insufficient laboratory capacity, misdiagnosis and prevalence of extensive antibiotic use in India. Lack of access to healthcare also increases under-reporting, thus bringing the reliability of the data into question. Conjugate meningococcal vaccines are being used for disease prevention by national governments and immunization programs globally. In India, meningococcal vaccination is recommended only for certain high-risk groups, during outbreaks and for international travelers such as Hajj pilgrims and students pursuing studies abroad.

conclusionMeningococcal disease is prevalent in India but remains grossly underestimated and under-reported. Available literature largely presents outbreak data related to serogroup A disease; however, non-A serogroup disease cases have been reported. Reliable epidemiologic data are urgently needed to inform the true burden of endemic disease. Further research into the significance of meningococcal disease burden can be used to improve public health policy in India. Fig. 1 Plain language summary.

Indexed as

AdolescentsAdultsChildrenImmunizationIndiaMenACWY vaccineMeningococcal diseaseMortalityOutbreaksUnder-reporting

Identifiers

PMID32705485
PMCPMC7376278
OpenAlexW3044241007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.